Sequoia Financial Advisors LLC Has $776,000 Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Sequoia Financial Advisors LLC increased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,296 shares of the biopharmaceutical company’s stock after purchasing an additional 167 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $776,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Regeneron Pharmaceuticals Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $1,045,822,000. Geode Capital Management LLC increased its position in Alnylam Pharmaceuticals by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock valued at $589,209,000 after acquiring an additional 66,928 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Alnylam Pharmaceuticals by 5.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 513,962 shares of the biopharmaceutical company’s stock valued at $120,940,000 after acquiring an additional 26,614 shares in the last quarter. Swiss National Bank increased its position in Alnylam Pharmaceuticals by 0.3% in the 3rd quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock valued at $103,246,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Eagle Asset Management Inc. increased its position in Alnylam Pharmaceuticals by 25.7% in the 3rd quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock valued at $85,889,000 after acquiring an additional 63,385 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $241.76 on Monday. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The company has a market capitalization of $31.30 billion, a P/E ratio of -111.41 and a beta of 0.39. The company’s 50 day moving average price is $255.17 and its two-hundred day moving average price is $259.96. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the sale, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 71,234 shares of company stock worth $19,958,097. Company insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on ALNY. Royal Bank of Canada restated an “outperform” rating and issued a $310.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Sanford C. Bernstein lowered their price objective on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. JPMorgan Chase & Co. raised their price objective on shares of Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the company a “neutral” rating in a research report on Tuesday, March 11th. Chardan Capital reaffirmed a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Finally, William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have given a buy rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $304.26.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.